Solana Beach, CA, United States

Evoke Pharma Reaffirms Its Commitment to Patients with Gastroparesis Amid Industry Developments

Gimoti remains the sole proprietary FDA approved treatment for symptoms of diabetic gastroparesis Gimoti remains the sole proprietary FDA approved treatment for symptoms of diabetic gastroparesis

2024-09-19 18:20

Evoke Pharma to Participate in Gastroenterology and Hepatology Advanced Practice Providers (GHAPP) Annual Conference

SOLANA BEACH, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announc…

2024-09-09 12:30

Evoke Pharma to Present at H.C. Wainwright's 26th Annual Global Investment Conference

Evoke Pharma to Present at H.C. Wainwright's 26th Annual Global Investment Conference

2024-09-04 13:32

Evoke Pharma to Present at H.C. Wainwright’s 26th Annual Global Investment Conference

SOLANA BEACH, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announc…

2024-09-04 13:20